To the Editor, Coronavirus disease 2019 (COVID-19) is a novel worldwide pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Children and adolescents generally present with mild symptoms. Nevertheless, 0.14% of them can develop a lifethreatening complication, the multisystem inflammatory syndrome in children (MIS-C). 1 This rare but serious condition can lead to multiorgan failure. To date, ocular reports associated with MIS-C are scarce. We report a case of bilateral intermediate uveitis in a healthy teenager with MIS-C secondary to COVID-19 infection.A 14-year-old male, the healthy adolescent was admitted for high-grade fever, vomiting, and rash for 3 days. Initial nasopharyngeal swab for COVID-19 reverse transcriptase-polymerase chain reaction (RT-PCR) was positive and dengue serology was negative.On Day 3 of admission, his condition deteriorated with presumed septic shock, myocarditis with pericardial effusion, pleural effusion, and transaminitis. His lowest blood pressure was 87/48 mmHg with a heart rate of 147 bpm and the highest temperature was 40.4°C. He was transferred to the intensive care unit and a comprehensive workup was performed. Notable markedly elevated laboratory investigations were inflammatory markers like C-reactive protein of 10.83 mg/dl and procalcitonin of 16.14 ng/ml. Other elevated levels include D-dimer level (10.13 µg/ml), ferritin (916.23 µg/L), troponin (176 µg/L), and lactate dehydrogenase (336 µ/L). Infective screenings like blood, urine, and stool cultures were negative. Computed tomography angiogram of the thorax showed minimal pericardial effusion and bilateral pleural effusion with no evidence of coronary artery aneurysm or pulmonary thrombosis. The diagnosis was revised to MIS-C secondary to COVID-19 infection. He required inotrope support for 3 days and received two doses of intravenous immunoglobulin 1 g/kg; subcutaneous enoxaparin 40 mg od for 7 days and intravenous dexamethasone 0.2 mg/kg for 5 days followed by oral dexamethasone tapered within a month. Intravenous ceftriaxone 1 g bd for 7 days and intravenous azithromycin 250 mg od for 5 days were given as prophylaxis.